vs
Side-by-side financial comparison of Gogo Inc. (GOGO) and Pacira BioSciences, Inc. (PCRX). Click either name above to swap in a different company.
Gogo Inc. is the larger business by last-quarter revenue ($230.6M vs $177.4M, roughly 1.3× Pacira BioSciences, Inc.). Pacira BioSciences, Inc. runs the higher net margin — 1.6% vs -4.3%, a 6.0% gap on every dollar of revenue. On growth, Gogo Inc. posted the faster year-over-year revenue change (67.3% vs 5.0%). Over the past eight quarters, Gogo Inc.'s revenue compounded faster (48.7% CAGR vs -0.2%).
Gogo Inc. is an American provider of in-flight broadband Internet service and other connectivity services for business aircraft, headquartered in Broomfield, Colorado. Through its Gogo LLC subsidiary, Gogo previously provided in-flight WiFi to 17 airlines until the Commercial Air business was sold to Intelsat for $400 million in December 2020. According to Gogo, over 2,500 commercial aircraft and 6,600 business aircraft have been equipped with its onboard Wi-Fi services. The company is the de...
Pacira BioSciences, Inc. is a specialty pharmaceutical company focused on developing and commercializing non-opioid pain management solutions. Its core product line targets post-surgical pain relief for patients, serving hospitals, ambulatory surgery centers and other healthcare providers primarily in the U.S., with ongoing expansion efforts in select international markets.
GOGO vs PCRX — Head-to-Head
Income Statement — Q4 FY2025 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $230.6M | $177.4M |
| Net Profit | $-10.0M | $2.9M |
| Gross Margin | — | — |
| Operating Margin | 6.2% | 3.9% |
| Net Margin | -4.3% | 1.6% |
| Revenue YoY | 67.3% | 5.0% |
| Net Profit YoY | 64.6% | — |
| EPS (diluted) | $-0.08 | $0.07 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | — | $177.4M | ||
| Q4 25 | $230.6M | $196.9M | ||
| Q3 25 | $223.6M | $179.5M | ||
| Q2 25 | $226.0M | $181.1M | ||
| Q1 25 | $230.3M | $168.9M | ||
| Q4 24 | $137.8M | $187.3M | ||
| Q3 24 | $100.5M | $168.6M | ||
| Q2 24 | $102.1M | $178.0M |
| Q1 26 | — | $2.9M | ||
| Q4 25 | $-10.0M | — | ||
| Q3 25 | $-1.9M | $5.4M | ||
| Q2 25 | $12.8M | $-4.8M | ||
| Q1 25 | $12.0M | $4.8M | ||
| Q4 24 | $-28.2M | — | ||
| Q3 24 | $10.6M | $-143.5M | ||
| Q2 24 | $839.0K | $18.9M |
| Q1 26 | — | — | ||
| Q4 25 | — | 79.5% | ||
| Q3 25 | — | 80.9% | ||
| Q2 25 | 87.8% | 77.4% | ||
| Q1 25 | 87.3% | 79.7% | ||
| Q4 24 | — | 78.7% | ||
| Q3 24 | — | 76.9% | ||
| Q2 24 | — | 75.1% |
| Q1 26 | — | 3.9% | ||
| Q4 25 | 6.2% | 1.2% | ||
| Q3 25 | 12.9% | 3.5% | ||
| Q2 25 | 15.9% | 4.7% | ||
| Q1 25 | 15.3% | 1.2% | ||
| Q4 24 | -17.5% | 13.2% | ||
| Q3 24 | 19.0% | -82.8% | ||
| Q2 24 | 21.2% | 15.9% |
| Q1 26 | — | 1.6% | ||
| Q4 25 | -4.3% | — | ||
| Q3 25 | -0.9% | 3.0% | ||
| Q2 25 | 5.7% | -2.7% | ||
| Q1 25 | 5.2% | 2.8% | ||
| Q4 24 | -20.5% | — | ||
| Q3 24 | 10.6% | -85.1% | ||
| Q2 24 | 0.8% | 10.6% |
| Q1 26 | — | $0.07 | ||
| Q4 25 | $-0.08 | $0.05 | ||
| Q3 25 | $-0.01 | $0.12 | ||
| Q2 25 | $0.09 | $-0.11 | ||
| Q1 25 | $0.09 | $0.10 | ||
| Q4 24 | $-0.22 | $0.38 | ||
| Q3 24 | $0.08 | $-3.11 | ||
| Q2 24 | $0.01 | $0.39 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $125.2M | $144.3M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $101.1M | $653.9M |
| Total Assets | $1.3B | $1.2B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $144.3M | ||
| Q4 25 | $125.2M | $238.4M | ||
| Q3 25 | $133.6M | $246.3M | ||
| Q2 25 | $102.1M | $445.9M | ||
| Q1 25 | $70.3M | $493.6M | ||
| Q4 24 | $41.8M | $484.6M | ||
| Q3 24 | $176.7M | $453.8M | ||
| Q2 24 | $161.6M | $404.2M |
| Q1 26 | — | — | ||
| Q4 25 | — | $372.2M | ||
| Q3 25 | — | $376.7M | ||
| Q2 25 | — | $580.5M | ||
| Q1 25 | — | $583.4M | ||
| Q4 24 | — | $585.3M | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
| Q1 26 | — | $653.9M | ||
| Q4 25 | $101.1M | $693.1M | ||
| Q3 25 | $107.0M | $727.2M | ||
| Q2 25 | $102.8M | $757.8M | ||
| Q1 25 | $82.9M | $798.5M | ||
| Q4 24 | $69.3M | $778.3M | ||
| Q3 24 | $52.7M | $749.6M | ||
| Q2 24 | $52.0M | $879.3M |
| Q1 26 | — | $1.2B | ||
| Q4 25 | $1.3B | $1.3B | ||
| Q3 25 | $1.3B | $1.3B | ||
| Q2 25 | $1.3B | $1.5B | ||
| Q1 25 | $1.2B | $1.6B | ||
| Q4 24 | $1.2B | $1.6B | ||
| Q3 24 | $810.7M | $1.5B | ||
| Q2 24 | $802.7M | $1.6B |
| Q1 26 | — | — | ||
| Q4 25 | — | 0.54× | ||
| Q3 25 | — | 0.52× | ||
| Q2 25 | — | 0.77× | ||
| Q1 25 | — | 0.73× | ||
| Q4 24 | — | 0.75× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $8.5M | — |
| Free Cash FlowOCF − Capex | $-25.4M | — |
| FCF MarginFCF / Revenue | -11.0% | — |
| Capex IntensityCapex / Revenue | 14.7% | — |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $65.1M | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $8.5M | $43.7M | ||
| Q3 25 | $46.8M | $60.8M | ||
| Q2 25 | $36.7M | $12.0M | ||
| Q1 25 | $32.5M | $35.5M | ||
| Q4 24 | $-38.3M | $33.1M | ||
| Q3 24 | $25.1M | $53.9M | ||
| Q2 24 | $24.9M | $53.2M |
| Q1 26 | — | — | ||
| Q4 25 | $-25.4M | $43.5M | ||
| Q3 25 | $27.3M | $57.0M | ||
| Q2 25 | $33.5M | $9.3M | ||
| Q1 25 | $29.7M | $26.9M | ||
| Q4 24 | $-42.6M | $31.0M | ||
| Q3 24 | $20.7M | $49.8M | ||
| Q2 24 | $21.6M | $51.6M |
| Q1 26 | — | — | ||
| Q4 25 | -11.0% | 22.1% | ||
| Q3 25 | 12.2% | 31.7% | ||
| Q2 25 | 14.8% | 5.1% | ||
| Q1 25 | 12.9% | 15.9% | ||
| Q4 24 | -30.9% | 16.6% | ||
| Q3 24 | 20.6% | 29.6% | ||
| Q2 24 | 21.1% | 29.0% |
| Q1 26 | — | — | ||
| Q4 25 | 14.7% | 0.1% | ||
| Q3 25 | 8.7% | 2.2% | ||
| Q2 25 | 1.4% | 1.5% | ||
| Q1 25 | 1.2% | 5.1% | ||
| Q4 24 | 3.1% | 1.1% | ||
| Q3 24 | 4.4% | 2.4% | ||
| Q2 24 | 3.3% | 0.9% |
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | 11.20× | ||
| Q2 25 | 2.87× | — | ||
| Q1 25 | 2.70× | 7.37× | ||
| Q4 24 | — | — | ||
| Q3 24 | 2.36× | — | ||
| Q2 24 | 29.74× | 2.82× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
GOGO
| Services | $191.9M | 83% |
| Products | $38.7M | 17% |
| Fcc Reimbursement Program | $2.0M | 1% |
PCRX
| EXPAREL | $143.3M | 81% |
| ZILRETTA | $26.8M | 15% |
| iovera° | $6.2M | 3% |
| Bupivacaine liposome injectable suspension | $1.2M | 1% |
